CAPR Stock Price, Capricor Therapeutics Quote, Chart

Market Summary

USD5.24-0.09

Market Closed

-1.69%

CAPR Stock Price

View Fullscreen

CAPR RSI Chart

CAPR Valuation

Market Cap

164.5M

Price/Earnings (Trailing)

-7.38

Price/Sales (Trailing)

6.53

Price/Free Cashflow

-6.11

CAPR Price/Sales (Trailing)

CAPR Profitability

Return on Equity

-98.61%

Return on Assets

-37.95%

Free Cashflow Yield

-16.35%

CAPR Fundamentals

CAPR Revenue

Revenue (TTM)

25.2M

Rev. Growth (Yr)

1.2K%

Rev. Growth (Qtr)

95.42%

CAPR Earnings

Earnings (TTM)

-22.3M

Earnings Growth (Yr)

90.13%

Earnings Growth (Qtr)

88.07%

Breaking Down CAPR Revenue

Last 7 days

1.8%

Last 30 days

-23.9%

Last 90 days

32.0%

Trailing 12 Months

36.5%

How does CAPR drawdown profile look like?

CAPR Financial Health

Current Ratio

1.63

CAPR Investor Care

Shares Dilution (1Y)

21.99%

Diluted EPS (TTM)

-0.83

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	5.5M	9.5M	14.0M	25.2M
2022	0	0	1.8M	2.6M
2021	165.4K	319.6K	302.7K	244.9K
2020	960.2K	599.7K	474.5K	310.3K
2019	1.5M	1.5M	1.4M	1.0M
2018	2.2M	1.6M	1.5M	1.7M
2017	3.7M	3.5M	3.1M	2.7M
2016	4.9M	4.8M	4.2M	4.0M
2015	5.5M	5.8M	5.8M	5.5M
2014	1.3M	2.2M	3.4M	4.8M
2013	1.9M	2.1M	2.2M	503.2K
2012	1.5M	1.6M	1.8M	1.9M
2011	0	0	0	1.4M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Capricor Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 23, 2024	collier earl m jr	acquired	41,700	1.39	30,000	-
Apr 23, 2024	musket david b	acquired	22,456	1.39	16,156	-
Oct 23, 2023	bergmann anthony	acquired	3,027	1.39	2,178	chief financial officer
Oct 12, 2023	musket david b	bought	1,127	2.75	410	-
Oct 10, 2023	collier earl m jr	bought	28,300	2.83	10,000	-
Oct 09, 2023	musket david b	bought	14,334	2.82	5,083	-
Oct 06, 2023	auwaerter paul gisbert	bought	14,200	2.84	5,000	-
Oct 04, 2023	musket david b	bought	7,250	2.9	2,500	-
Aug 14, 2023	litvack frank	acquired	28,839	1.39	20,748	-
Aug 14, 2023	litvack frank	sold (taxes)	-28,846	6.61	-4,364	-

Which funds bought or sold CAPR recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
May 01, 2024	BNP PARIBAS FINANCIAL MARKETS	new	-	39,565	39,565	-%
Apr 30, 2024	Harel Insurance Investments & Financial Services Ltd.	unchanged	-	2,000	5,000	-%
Apr 29, 2024	COMMONWEALTH EQUITY SERVICES, LLC	unchanged	-	58,000	210,000	-%
Apr 26, 2024	YHB Investment Advisors, Inc.	new	-	1,019	1,019	-%
Apr 25, 2024	SIMPLEX TRADING, LLC	reduced	-41.05	-37,000	171,000	-%
Apr 25, 2024	Bank of New York Mellon Corp	reduced	-16.54	65,867	480,339	-%
Apr 23, 2024	Main Street Financial Solutions, LLC	new	-	135,800	135,800	0.01%
Apr 18, 2024	McGlone Suttner Wealth Management, Inc.	sold off	-100	-2,068	-	-%
Mar 11, 2024	VANGUARD GROUP INC	added	1.14	1,757,900	5,698,830	-%

Are Funds Buying or Selling CAPR?

Are funds buying CAPR calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CAPR

No. of Funds

Unveiling Capricor Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 07, 2024	highbridge capital management llc	9.1%	2,789,699	SC 13G
Oct 17, 2023	nippon shinyaku co ltd	6.97%	2,145,922	SC 13G
Aug 03, 2021	feinberg larry n	0.00%	0	SC 13G/A
Feb 08, 2021	feinberg larry n	9.78%	2e+06	SC 13G
Dec 27, 2019	armistice capital, llc	4.99%	243,184	SC 13G

Recent SEC filings of Capricor Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
Apr 29, 2024	8-K	Current Report
Apr 25, 2024	4	Insider Trading
Apr 24, 2024	4	Insider Trading
Apr 01, 2024	DEF 14A	DEF 14A
Apr 01, 2024	ARS	ARS
Mar 20, 2024	PRE 14A	PRE 14A
Mar 11, 2024	10-K	Annual Report
Feb 29, 2024	8-K	Current Report
Feb 16, 2024	S-8	Employee Benefits Plan
Feb 07, 2024	SC 13G	Major Ownership Report

Peers (Alternatives to Capricor Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	48.1B	6.8B	21.21%	-3.50%	-8.06	7.03	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.0B	2.0B	-0.48%	-24.66%	-57.25	9.49	75.20%	68.82%
BMRN	15.9B	2.5B	-3.50%	-10.49%	77.41	6.43	13.74%	186.89%
INCY	11.9B	3.8B	-4.91%	-21.97%	15.99	3.16	8.58%	129.81%
MID-CAP
APLS	5.7B	396.6M	-14.74%	-44.14%	-10.83	14.44	425.83%	18.94%
BBIO	5.2B	107.9M	-3.68%	92.64%	-9.5	48.09	54.84%	-28.31%
AXSM	3.5B	270.6M	-0.50%	3.10%	-14.69	12.99	440.80%	-27.84%
ARWR	3.0B	240.7M	-7.87%	-39.98%	-10.07	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-5.69%	-19.43%	-45.92	3.87	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-1.57%	-9.52%	24.79	4.45	85.90%	-14.05%
NVAX	659.2M	983.7M	3.97%	-34.13%	-1.21	0.67	-50.36%	17.16%
CRBP	400.8M	881.7K	1.98%	349.41%	-8.99	466.16	-77.61%	-5.33%
INO	280.7M	4.9M	-3.22%	25.10%	-2.08	57.68	-54.97%	51.71%
IBIO	7.0M	2.1M	-29.72%	84.40%	-0.26	2.14	-13.45%	66.37%

Capricor Therapeutics Inc News

Latest updates

Capricor Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2
Revenue	95.4%	12,088	6,186	3,917	2,987	960	1,592	-	-	204	41.00	58.00	17.00	50.00	186	222	142	410	231	648	219	404
Operating Expenses	2.4%	13,369	13,050	11,665	11,171	9,026	8,069	6,380	4,315	5,287	5,202	4,238	3,931	3,538	2,293	1,705	1,770	2,476	2,788	3,954	4,391	4,567
S&GA Expenses	13.5%	3,429	3,021	2,847	3,510	2,794	2,565	2,116	1,801	1,790	1,906	1,493	1,302	1,610	1,138	877	912	832	976	1,105	1,259	1,178
R&D Expenses	-0.9%	9,940	10,029	8,817	7,662	6,232	5,504	4,273	2,500	3,500	3,296	2,745	2,629	1,927	1,155	829	858	1,644	1,811	2,858	3,132	3,389
Interest Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	88.1%	-762	-6,390	-7,366	-7,768	-7,720	-6,371	-6,190	-3,931	-4,748	-5,151	-4,177	-3,910	-3,484	-2,084	-1,469	-1,606	-2,046	-2,519	-3,259	-4,136	-4,123
Net Income Margin	57.5%	-0.89*	-2.08*	-3.09*	-5.23*	-11.37*	-15.31*	-81.76*	-59.49*	-56.29*	-101.13*	-44.02*	-	-	-	-	-	-	-	-	-	-
Free Cashflow	-34.1%	-12,152	-9,064	-9,553	3,862	-7,596	-6,243	-5,996	-3,806	-4,836	-3,366	-4,130	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	58.1%	59.00	37.00	46.00	54.00	50.00	54.00	58.00	65.00	41.00	43.00	40.00	44.00	35.00	36.00	37.00	14.00	11.00	8.00	7.00	9.00	9.00
Current Assets	72.2%	51.00	30.00	39.00	47.00	43.00	48.00	53.00	60.00	36.00	41.00	39.00	43.00	34.00	35.00	37.00	14.00	11.00	7.00	7.00	8.00	8.00
Cash Equivalents	63.6%	15.00	9.00	10.00	11.00	10.00	8.00	16.00	58.00	35.00	41.00	38.00	42.00	33.00	35.00	36.00	13.00	4.00	7.00	6.00	7.00	5.00
Net PPE	8.2%	6.00	5.00	5.00	5.00	5.00	4.00	3.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	1.00	1.00	1.00
Liabilities	-7.2%	36.00	39.00	43.00	48.00	38.00	39.00	39.00	40.00	10.00	6.00	7.00	7.00	6.00	6.00	5.00	5.00	4.00	4.00	5.00	5.00	5.00
Current Liabilities	-5.0%	31.00	33.00	35.00	37.00	24.00	23.00	20.00	14.00	4.00	3.00	3.00	4.00	3.00	2.00	2.00	1.00	1.00	1.00	2.00	2.00	1.00
Shareholder's Equity	-	23.00	-	3.00	6.00	12.00	15.00	19.00	25.00	31.00	37.00	33.00	36.00	28.00	30.00	32.00	10.00	7.00	4.00	2.00	4.00	5.00
Retained Earnings	-0.5%	-159	-158	-152	-144	-137	-129	-122	-115	-108	-101	-97.94	-93.19	-88.04	-83.86	-79.95	-76.47	-74.38	-72.91	-71.30	-69.26	-66.74
Additional Paid-In Capital	16.0%	182	157	155	151	149	145	142	140	139	139	131	130	116	114	112	86.00	81.00	76.00	74.00	73.00	71.00
Accumulated Depreciation	-	2.00	-	-	-	1.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shares Outstanding	20.5%	31.00	26.00	26.00	25.00	25.00	24.00	24.00	24.00	24.00	23.00	23.00	22.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	120	-	-	-	83.00	-	-	-	115	-	-	-	87.00	-	-	-	9.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-31.8%	-11,594	-8,794	-9,417	4,210	-6,902	-5,685	-6,542	24,047	-5,627	-3,337	-4,514	-3,329	-3,842	-2,977	-2,016	-1,218	-1,785	-1,651	-1,777	-1,607	-3,771
Share Based Compensation	8.4%	1,862	1,717	1,619	2,195	1,148	1,087	1,158	1,065	780	720	712	753	474	487	704	288	128	225	124	223	391
Cashflow From Investing	-175.9%	-5,862	7,721	6,461	-3,211	5,142	-4,176	-35,412	-625	-368	-468	-322	-36.91	-288	-152	-107	5,987	-5,986	-	-	2,985	3,005
Cashflow From Financing	10378.9%	23,167	221	2,188	4.00	2,950	1,882	15.00	27.00	42.00	6,567	1,035	12,580	1,496	2,177	25,159	4,550	4,611	2,588	546	1,433	512
Buy Backs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	193*	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

CAPR Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
REVENUE
Revenue	$ 25,178,066	$ 2,551,469
TOTAL REVENUE	25,178,066	2,551,469
OPERATING EXPENSES
Research and development	36,448,039	21,816,949
General and administrative	12,807,886	10,431,903
TOTAL OPERATING EXPENSES	49,255,925	32,248,852
LOSS FROM OPERATIONS	(24,077,859)	(29,697,383)
OTHER INCOME (EXPENSE)
Other income	67,657	190,582
Investment income	1,728,701	521,535
Loss on disposal of fixed assets	(6,041)	(34,266)
TOTAL OTHER INCOME (EXPENSE)	1,790,317	677,851
NET LOSS	(22,287,542)	(29,019,532)
OTHER COMPREHENSIVE INCOME (LOSS)
Net unrealized gain on marketable securities	130,569	105,244
COMPREHENSIVE LOSS	$ (22,156,973)	$ (28,914,288)
Net loss per share, basic	$ (0.83)	$ (1.18)
Net loss per share, diluted	$ (0.83)	$ (1.18)
Weighted-average number of shares of common stock outstanding basic	26,778,360	24,552,688
Weighted-average number of shares of common stock outstanding diluted	26,778,360	24,552,688

CAPR Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($)	Dec. 31, 2023	Dec. 31, 2022
CURRENT ASSETS
Cash and cash equivalents	$ 14,694,857	$ 9,603,242
Marketable securities	24,792,846	31,818,020
Receivables	10,371,993	547,580
Prepaid expenses and other current assets	995,776	919,892
TOTAL CURRENT ASSETS	50,855,472	42,888,734
PROPERTY AND EQUIPMENT, net	5,560,641	4,588,030
OTHER ASSETS
Lease right-of-use assets, net	2,050,042	2,349,974
Other assets	268,172	268,172
TOTAL ASSETS	58,734,327	50,094,910
CURRENT LIABILITIES
Accounts payable and accrued expenses	6,222,762	4,834,683
Accounts payable and accrued expenses, related party	27,479	89,234
Lease liabilities, current	749,112	682,039
Deferred revenue, current	24,270,465	17,980,599
TOTAL CURRENT LIABILITIES	31,269,818	23,586,555
LONG-TERM LIABILITIES
CIRM liability	3,376,259	3,376,259
Lease liabilities, net of current	1,486,783	1,878,070
Deferred revenue, net of current	0	9,467,932
TOTAL LONG-TERM LIABILITIES	4,863,042	14,722,261
TOTAL LIABILITIES	36,132,860	38,308,816
COMMITMENTS AND CONTINGENCIES (NOTE 6)
STOCKHOLDERS' EQUITY
Preferred stock, $0.001 par value, 5,000,000 shares authorized, none issued and outstanding
Common stock, $0.001 par value, 50,000,000 shares authorized, 31,148,320 and 25,241,402 shares issued and outstanding, respectively	31,148	25,241
Additional paid-in capital	181,701,859	148,735,420
Accumulated other comprehensive income	235,813	105,244
Accumulated deficit	(159,367,353)	(137,079,811)
TOTAL STOCKHOLDERS' EQUITY	22,601,467	11,786,094
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 58,734,327	$ 50,094,910

About Capricor Therapeutics Inc

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD). It also focused on developing StealthX, an engineered exosome platform technology which generated two vaccine candidates, such as STX-S and STX-N, induced an immune response against two SARS-CoV-2 proteins, spike, and nucleocapsid, as well as developing vaccines and therapeutics for infectious and monogenic diseases, and other potential indications. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.

CEO	Dr. Linda MarbÃƒÂ¡n Ph.D.
WEBSITE	capricor.com
INDUSTRY	Biotechnology
EMPLOYEES	74

Capricor Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Capricor Therapeutics Inc? What does CAPR stand for in stocks?

CAPR is the stock ticker symbol of Capricor Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Capricor Therapeutics Inc (CAPR)?

As of Thu May 02 2024, market cap of Capricor Therapeutics Inc is 164.53 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CAPR stock?

You can check CAPR's fair value in chart for subscribers.

What is the fair value of CAPR stock?

You can check CAPR's fair value in chart for subscribers. The fair value of Capricor Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Capricor Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CAPR so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Capricor Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether CAPR is over valued or under valued. Whether Capricor Therapeutics Inc is cheap or expensive depends on the assumptions which impact Capricor Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CAPR.

What is Capricor Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 02 2024, CAPR's PE ratio (Price to Earnings) is -7.38 and Price to Sales (PS) ratio is 6.53. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CAPR PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Capricor Therapeutics Inc's stock?

In the past 10 years, Capricor Therapeutics Inc has provided -0.194 (multiply by 100 for percentage) rate of return.